

ASX Announcement and Media Release

13 January 2004

SciGen Limited

SciGen reaches another important milestone as recombinant human insulin achieves health registration in Vietnam.

SciGen Limited ("SciGen") announced today that it has secured registration of its second generation recombinant human insulin (SciLin™) in Vietnam. This is the first registration of SciLin in the Asia Pacific Region.

Final preparations for the launch and sales of SciLin in Vietnam are underway and sales are expected to commence in coming weeks. Best estimates available indicate the size of the Vietnamese insulin market to be in excess of US\$30M. SciGen has had an established sales team in Vietnam for the last year and this team has been further enhanced to ensure best efforts are given to achieving sales targets for SciLin.

SciGen has previously launched its 3rd generation hepatitis B Vaccine (Sci-B-Vac™) in Vietnam and this has led the company to establish local networks and the profile of SciGen, which will in turn facilitate sales of SciLin, both in the government and private markets.

Registration applications for SciLin are still active in India, Indonesia and Pakistan with dossier preparation and other negotiations underway in other key territories in the Region such as China. The likely registration date of SciLin in India has been pushed back to the end of Q1 CY04 due to regulatory agency requirements and processes.

Registration of SciLin (and SciGen's other products) will continue to be pursued in appropriate markets in the Asia Pacific Region.

The registration of SciGen's human insulin (SciLin™) in Vietnam is a very important step for SciGen in that it further demonstrates SciGen's competency in delivering the healthcare registration of its products and the Company is able to capitalise upon the commercialization potential of products in the later phases of development.

About SciGen

SciGen Ltd is a progressive biotechnology/biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singaporean biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has offices in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, Indonesia, Israel, Poland and the Netherlands.

====ENDS====

Media enquiries

Mark Compton
Managing Director & CEO
Telephone: +61 2 9234 1700

Web: www.scigen.com.au